America, is caused by the thermodimorphic human pathogens Paracoccidioides 64 brasiliensis and Paracoccioidioides lutzii. After inhalation of airborne propagules 65 from fungal mycelia phase, in the lungs the fungi convert into the infectious form -66 yeast phase (1-3). The yeast can spread to several organs causing systemic disease (4). 67
Human defense against PCM depends on satisfactory cellular immune response and 68 cytokine production (5, 6) . Immune mechanisms that prevented cell division and 69 budding of the fungal cells could aid in the control the PCM. 70
Extracellular vesicles (EVs) are produced by all living cells, and actively 71 participate as key regulators of physiopathological mechanisms during fungal 72 infections (7, 8) . Fungal EVs carry several virulence factors and other important 73 molecules, contributing to fungal pathogenicity and host immunomodulation (9) (10) (11) (12) (13) (14) . 74
Since EVs plays significant roles in the host-pathogen relationship, the vesicular 75 stability is important to ensure suitable delivery of their cargo into host cells (13, 15) . 76
Bacterial and eukaryotic pathogens present surface glycans that may be 77 recognized by host carbohydrate-binding proteins. These interactions commonly 78 affect the microorganism pathogenesis, the host immune response or the success of 79 intracellular parasitism (16) (17) (18) (19) . Recently, we have reported that Galectin-3 (Gal-3), a 80 β-galactoside-binding animal lectin, plays significant roles in cryptococcal infection 81 (13). Gal-3 interferes the C. neoformans infection, inhibiting C. neoformans growth 82 and promoting vesicle disruption (13). Also, Gal-3 has been reported to influence the 83 outcome of other mycoses, such as Candida albicans (20) and Histoplasma 84 capsulatum (21). In Paracoccidioides brasiliensis, Gal-3 was reported to play an 85 immunomodulatory role in the host response (22). Since Gal-3 can influence host 86 response against PCM, as well as several other microbial infections, and regulates 87 different functions in the physiopathology of infections, we explored whether Gal-3 88 influence P. brasiliensis growth and vesicle stability. 89
In this work, we assessed the Gal-3 levels in humans and mice with PCM. Also, 90
we demonstrated the influence of Gal-3 in the P. brasiliensis growth and stability of 91
EVs. Our results demonstrate that Gal-3 inhibits growth and budding of P. 92 brasiliensis yeast cells, and promotes vesicle disruption. Our results suggest that Gal-93 after 72 h compared with the controls (denatured Gal-3 treated or PBS) ( Figure 3 ). To 120 verify whether Gal-3 treatment of fungal yeast induces yeast death, we performed 121 viability assays using fluorescein diacetate/ethidium bromide staining. Gal-3 treated 122 and control cultures contained similar proportions of viable cells up until 72 h after 123
Gal-3 treatment, and all cultures were >80% viable (data not shown). To further 124 characterize Gal-3 effects in the growth of P. brasiliensis, we evaluated the average 125 number of cells with buds in the yeast culture in the presence or absence of Gal-3 for 126 72h, as well as in the presence of denatured Gal-3. We counted the budded or 127 unbudded yeast cell via direct observation in a Neubauer chamber ( Figure 3B ). The 128 average number of budding cells was 80% in both untreated and denatured Gal-3-129 treated cells. On the other hand, the average was decreased to 49% in Gal-3-treated 130
cells. 131
Flow cytometry assessment of the Gal-3 binding to P. brasiliensis Pb18 strain 132 showed that Gal-3 bound to P. brasiliensis cells ( Figure 4A ). Confocal microscopy 133 demonstrated that Gal-3 co-localized with calcofluor white, a cell wall dye ( Figure  134 4B-D and Supplementary Figure 1 ). Calcofluor white was used as a positive control 135 as it binds to the cell wall (CW). These results suggest that the recognition of the 136 fungal cell wall by Gal-3, through an unknown sugar moiety, may explain its 137 inhibitory effect in P. brasiliensis in vitro growth. 138
Gal-3 disrupted P. brasiliensis EVs 139
Exposure of EVs produced by C. neoformans to Gal-3, macrophages, or 140 bovine serum albumin causes vesicular disruption (13, 15) . We asked whether Gal-3 141 would affect the stability of EVs produced by P. brasiliensis. Addition of Gal-3 to 142 radiolabeled EVs promoted vesicular disruption and subsequent radioactive release in a dose-dependent manner ( Figure 5A ). Furthermore, we blocked Gal-3 carbohydrate 144 recognition domain (CRD) by pre-incubating with N-acetyl-lactosamine (lactosamine, 145
Gal-3 glycoligand) and by Gal-3 denaturation (boiling at 10 min for 100 °C). Both 146 denatured and lactosamine-bound Gal3 had no lytic effect on P. brasiliensis EVs 147 ( Figure 5A ), suggesting that intact 3D conformation and Gal-3 CRD are important for 148 the Gal-3 lysing activity. Moreover, radioactive assays showed that other lectins were 149 unable to lyse P. brasiliensis EVs ( Figure 5B ). 150
Gal-3 affects macrophages capability to disrupt and internalize EVs 151
Given that Gal-3 is expressed and play a myriad roles in macrophage 152 populations (25-27) and on the previous observation that macrophages (15) and Gal-3 153 can disrupt EVs from C. neoformans (13) and P. brasiliensis (this study), we 154 evaluated whether these Gal3 binding and EV lysis could be correlated for P. 155
brasiliensis. The addition of radiolabeled EVs from P. brasiliensis to the 156 macrophages showed that WT peritoneal macrophages were approximately three 157 times more effective than Gal-3 -/macrophages to disrupt EVs (black bars, Figure 6) . 158
Moreover, we demonstrated that uptake of EVs from P. brasiliensis by WT peritoneal 159 macrophages gradually increased, whereas the uptake by Gal-3 -/peritoneal 160 macrophages increased significantly less ( Figure 6 ). Herein we describe a role for Gal-3 in P. brasiliensis infection that parallels 166 recent observations with C. neoformans (13). Galectins are able to regulate positively 167 or negatively host-microbial interactions in respiratory infections according to 168 galectin type, pathogen and host context (28, 29). Gal-3, member of the galectin family of β-galactosides-binding proteins, is widely expressed in different cells, and 170 plays important roles in biological phenomena, such as inflammation and immunity 171 (28, 30) . 172
Our previous results in experimental models of cryptococcosis showed Gal-3 173 were increased during infection (13). This observation was replicated in human serum 174
where higher levels of Gal-3 were detected in patients with cryptococcosis when 175 compared with healthy individuals (13). The low number of patients available for 176 study prevented us from making definitive statements regarding increase of Gal-3 in 177 human infection, but in a prior study (13) Gal-3 was shown to be increased in 178 infection and therefore it is very likely that the increase we observed is true in P. 179 brasiliensis infection. Moreover, our results show that Gal-3 inhibits the fungal 180 growth and morphogenesis of P. brasiliensis, a fungistatic effect of Gal-3 comparable 181
to what was previously verified for C. neoformans (13). In mouse models deficiency 182 of Gal-3 lead to an increased microbe burden and a decreased survival of the animals 183 (13, 20, 22, 31) . Furthermore gal3 -/mice die faster than wild-type mice when 184 infected with P. brasiliensis (22). Gal-3 antifungal effects are widely conserved, 185 affecting most (if not all) fungal pathogens and reaffirming Gal-3 as a critical player 186 in antifungal defenses. 187
Gal-3 promoted disruption of C. neoformans EVs and influenced the uptake of 188 EV content by macrophages (13), and we now replicate these observations for P. 189 brasiliensis. The disruption mechanism of EVs remains cryptic. As discussed 190 previously (13), albumin induce vesicles disruption (15) and albumin can bind to fatty 191 acids (32) and sterols (33) and may promote membrane destabilization. However we 192 cannot propose a similar mechanism for Gal-3 mediated disruption of EVs, 193 particularly since Gal-3 is not known to bind lipids. We showed Gal-3 disrupts EVs in a manner dependent on denaturation and the CRD domain, and we hypothesize the 195 existence of a novel mechanism of EV disruption. Gal-3 binds beta-galactosides, in 196 proteins (34) and microbe surfaces (specifically the fungal cell wall), and it is likely 197 that a version of this galactoside is displayed on the surface of microbial EVs. Further 198 studies are needed to discern the glycan moiety recognized in fungal EVs (and 199 whether the glycan moiety is associated to proteins or instead to an putative 200 carbohydrate polymers present in EVs) and how this binding triggers collapse of the 201 lipid bilayer to disrupt EVs. In any case, this may constitute an important mechanism 202 of immune defense: Gal-3 lysis of EVs would prevent EVs' delivery of a concentrated 203 cargo of virulence factors at the host cell surface and instead result in diluted release 204 of fungal components into the extracellular milieu and heightened degradation by host 205 extracellular enzymes. 206
We conclude that Gal-3 is beneficial for the mammalian host during P. 207 brasiliensis infection by contributing to host defense. As previously reported for C. 208 neoformans (13), the antimicrobial mechanism of Gal-3 is due to a combination of 209 microbial vesicle lysis, coupled to inhibition of fungal growth and morphogenesis. In 210 addition to direct antimicrobial effects, Gal-3 plays immunomodulatory roles (31, 37) that may synergize with the antimicrobial effects. Multiple inhibitors of Gal-3 212 have been designed (38) -and are being tested for antitumorigenic properties. 213
However our data reveals that these therapies may predispose patients for fungal 214 infections and, as is the case for many immunotherapies, it is important to closely 215 monitor fungal infections in these patients. In the case of fungal infections, it may be 216 desirable to design a Gal-3 mimetic that, through inhibition of growth and 217 interference with EV release, would act as a potent antifungal therapy. 218 219 220
METHODS

222
Ethics statement 223
All animal use complied with the standards described in Ethical Principles Guide in 
Mice and P. brasiliensis strain 233
We used male C57BL/6 (wild-type, WT, Jax 000664) and galectin-3-deficient mice 234 (gal3 -/-) at 6 to 8 weeks of age. Knockout mice were kindly donated by FT Liu 235 (University of California, Davis, CA). Gal3 -/mice were previously generated as 236 described and crossbred to the C57BL/6 mouse background for nine generations (39). 237
The animals were housed in the animal facility of the Ribeirao Preto Medical School, 238
University of São Paulo, under optimized hygienic conditions. All P. brasiliensis 239 experiments were performed with the Pb18 isolate. Fungal cultures were grown in the 240 YPD medium (2% peptone, 1% yeast extract, and 2% glucose) in the yeast phase, at 241 36 °C. To ensure yeast virulence, serial passages in BALB/c mice were performed 242 before the isolate Pb18 was used in experiments. 
Cell viability and growth in the presence of Gal-3 263
Fungal viability was determined using fluorescein diacetate/ethidium bromide 264 staining. Only the cultures that were greater than 85% viable were used. 265
To verify Gal-3 effect on the cells, we performed growth curves in YPD liquid 266 medium containing different concentrations of Gal-3 (Gal-3 human recombinant, 267 expressed in E. coli, Sigma-Aldrich) in a 96-well plate (Costar, NY, USA). The Gal-3 268 effect on cell proliferation was determined using an MTT assay (40), as follows: P. 269 brasiliensis yeast cells were suspended in YPD medium at a density of 10 6 cells/ml, and Gal-3, denatured Gal-3 or PBS were used as control. After incubation at 37°C in 271 an orbital shaker (150 rpm) for 120 h. To verify the Gal-3 effect in the yeast budding, 272
we assessed the average number of Pb18 strain cells with buds found in yeasts 273 cultures after 72 h of Gal-3 treatment and compared to the cells treated with denatured 274
Gal-3 and PBS treated. Counting was carried out in a neubauer chamber by optical 275 microscopy, considering as budding cells, the yeasts that presented at least one or 276 more bud. 277 278
Gal-3 binding assay and confocal microscopy 279
The Gal-3 binding assay and confocal microscopy were performed as previously 280 described for C. neoformans (13) using P. brasiliensis yeast cells. Gal-3 binding assay 281 was performed with yeast cells incubated with PBS containing 10% fetal bovine 282 serum for 20 min at 4°C to block non-specific binding of antibodies. Next, 1 ml of the 283 suspension containing 10 6 cells were incubated with either Gal-3 (40 µg/ml) and 284 denatured Gal-3 (40 µg/ml) for 40 min at 4°C. Cells were washed twice with PBS and 285 anti-Gal-3 antibody (1:50; Sigma-Aldrich) was added; after incubation for 45 min, the 286 cells were washed twice with PBS and incubated with anti-rabbit IgG-FITC antibody 287
(1:50; Sigma-Aldrich) for 40 min at 4°C. Gal-3 binding to P. brasiliensis cells was 288 analyzed by flow cytometry (Guava easyCyte, Guava Technologies, Millipore, 289
Hayward, CA, USA). Anti-rabbit IgG-FITC antibody associated or not with Gal-3 290 and WGA lectin (30 µg/ml) were, used as negative and positive controls, respectively. 291
The confocal microscopy was performed with cells incubated with Gal-3 (40 µg/ml) 292 at 37°C for 1 h followed by three washes with PBS and fixation with PBS-buffered 293 3.7% formaldehyde at 25°C. The samples were washed three times with PBS and 294 treated with glycine 0.1 M for 15 min, and blocked with BSA (1% in PBS) for 1 h at 295 25°C. Then, the cells were incubated with a rabbit anti-Gal-3 antibody Aldrich) overnight at 4°C. The samples were washed five times with PBS and 297 incubated for 1 h with FITC-labeled donkey anti-rabbit IgG from Jackson Immuno 298
Research Laboratories. For cell wall staining, samples were incubated with Calcofluor 299
White (50 µg/ml, Sigma-Aldrich) in PBS for 20 min. After five washes with PBS, 300 cells were placed on slide and coverslips mounted with Fluoromount-G (Electron 301
Microscopy Sciences). The samples were examined with a LSM780 system 302 AxioObserver, 63X oil immersion (Carl Zeiss, Jena, Germany). The images were 303 analyzed offline using the ImageJ software (http://rsb.info.nih.gov/ij/). Secondary 304 antibody alone was used as controls. All controls were negative. 305 306
Analysis of the stability of extracellular vesicles 307
EVs were isolated as previously described (41). Vesicles quantification was measured 308 by Nanoparticle-Tracking Analysis (NTA) using a NanoSight NS300 (Malvern 309
Instruments, Malvern, UK) equipped with fast video capture and particle-tracking 310 software, as previously described (14). Purified vesicles from P. brasiliensis were 311 diluted into PBS, and each sample was then injected into a NanoSight sample cubicle. 312
The measurements were obtained in triplicate and analyzed using NanoSight software 313 (version 3.2.16). The EVs stability was evaluated according to protocols previously 314 described (13). EVs were incubated with Gal-3 (Gal-3 human recombinant, expressed 315 in E. coli, Sigma-Aldrich) at different final concentration (0 to 10 µg/ml), and the 316 concentrations of all control lectins were normalized according to carbohydrate 317 binding sites. EVs stability was examined by radioactive assay through cultivation of 318 P. brasiliensis in the presence of [1-14 C] palmitic acid, as previously described for C. 319 neoformans (13, 15) . The suspension of radiolabeled EVs was incubated with Gal-3 at 37°C for different times and concentrations, and the suspension was ultracentrifuged 321 at 100,000 X g for 1 h at 4°C. Supernatants and pellets were saved for scintillation 322 counting. 323 324
Vesicle disruption and uptake by macrophages 325
To assess the vesicle stability and vesicle uptake by macrophages from WT and gal3 -/-326 mice, we used the protocol previously described (13). Peritoneal macrophages were 327 obtained from C57BL/6 WT or gal3 -/mice, and grown in DME medium (Invitrogen) 328 supplemented with 10% (v/v) fetal bovine serum, 10% NCTC (Invitrogen), 1% 329 nonessential amino acids (Invitrogen) and 1% penicillin (Invitrogen). 48-well tissue 330 culture plates were seeded with elicited peritoneal macrophages (4 x 10 5 cells/well). 331
EVs were obtained from P. brasiliensis cultures that were pulsed with [1-14 C] 332 palmitic acid 72 h before EVs harvesting, and added to macrophage cultures as 333 previously described (13). The adhered cells (containing EVs due to uptake), 334 supernatants (containing components of disrupted EVs) and pellets (containing intact 335 EVs) were saved for scintillation counting. The radioactivity distribution in the three 336 fractions was expressed as percent of the total radioactivity. 337 338
Statistical Analysis 339
Data are either the means of or representative results from at least 3 independent 340 experiments, each performed in triplicated. All statistical analyses and comparisons 341 were performed using the GraphPad Prism Software version 6.0 (GraphPad Software, 342
San Diego, CA, USA). A P value < 0.05 was considered statistically significant. 
